ECTRIMS 2021 - Physician's Weekly


Advertisement

ECTRIMS 2021

What causes NMOSD? Clues from a Canadian Cohort

Disease risk factors and the underlying etiology for neuromyelitis optica spectrum disorder (NMOSD) are not known. Using controls and the validated questionnaire from the Environmental Risk Factors in MS Study (EnvIMS) study [1]...

COVID-19 Vaccines Safe in Patients With NMOSD & MOGAD

While COVID-19 vaccines are recommended for people with neuromyelitis optica spectrum disorder (NMOSD) and MOG-antibody-associated disease (MOGAD), they were not specifically tested in this population, and thus, have an unclear...

Inebilizumab Sustains Efficacy & Safety During 5.5 Years

Investigators reported final safety and efficacy data from the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), in which patients aged 18 and older who had an Expanded Disability Status Scale...

Platelet-to-Lymphocyte Ratio Distinguishes MS From NMOSD

Previous studies have examined the platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios as biomarkers of inflammation and disease activity in autoimmune diseases. Researchers assessed the ability of these...

High Healthcare Use & Costs in Patients With NMOSD

Using a propensity score-matching methodology, investigators examined the economic and healthcare burden of neuromyelitis optica spectrum disorder (NMOSD). The study team performed a retrospective analysis of two claims datasets...

ECTRIMS 2021: Ponesimod vs Teriflunomide for RRMS

A total of 10 Janssen-sponsored data abstracts on MS research will be presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress from October 13 to 15, in Vienna,...

Loading

Advertisement

For latest news and updates
Email-id is invalid